Efficacy and Safety of Necitumumab Continuation Therapy in the Phase III SQUIRE Study of Patients With Stage IV Squamous Non–Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

Efficacy and Safety of Necitumumab Continuation Therapy in the Phase III SQUIRE Study of Patients With Stage IV Squamous Non–Small-Cell Lung Cancer

Published:2018-03 Issue:2 Volume:19 Page:130-138.e2
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Ciuleanu Tudor,Socinski Mark A.,Obasaju Coleman,Luft Alexander V.,Szczesna Aleksandra,Szafrański Wojciech,Ramlau Rodryg,Bálint Beatrix,Molinier Olivier,Depenbrock Henrik,Nanda Shivani,Paz-Ares Luis,Thatcher Nick

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference34 articles.

1. Metastatic non–small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Reck;Ann Oncol,2014

2. Global cancer statistics;Jemal;CA Cancer J Clin,2011

3. Treatment of non–small-cell lung cancer (NSCLC);Zarogoulidis;J Thorac Dis,2013

4. Genetic changes in squamous cell lung cancer: a review;Heist;J Thorac Oncol,2012

5. Squamous cell carcinoma of the lung: molecular subtypes and therapeutic opportunities;Perez-Moreno;Clin Cancer Res,2012

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Analysis of EGFR binding hotspots for design of new EGFR inhibitory biologics;Protein Science;2024-09-14

2. Epidermal growth factor receptor dual-target inhibitors as a novel therapy for cancer: A review;International Journal of Biological Macromolecules;2023-12

3. 20 years since the approval of first EGFR-TKI, gefitinib: Insight and foresight;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2023-11

4. Current status of anti-EGFR agents;Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies;2023

5. Non‐small cell lung cancer in China;Cancer Communications;2022-09-08